Vers la micro-élimination de l'hépatite C dans les prisons provinciales canadiennes


Nadine  Kronfli

Institut de recherche du Centre universitaire de santé McGill


Domaine : santé des populations

Programme Chercheurs-boursiers cliniciens - Junior 1

Concours 2019-2020

In Canada, chronic hepatitis C virus (HCV) infection causes more years of life lost than any other infectious disease, and affects approximately 252 000 Canadians. With the advent of safer, better tolerated and more effective treatment options for HCV, complete eradication of the virus (i.e. cure) is possible among 95% of those infected. While Canada has favoured the treatment of those with advanced liver disease, in order to eliminate HCV as a public health threat by 2030, treatment of asymptomatic, high-prevalence sub-populations who drive the HCV epidemic in Canada should be prioritized. One such sub-population is people in prison, among whom the prevalence of anti-HCV antibody is 40-fold higher than in the general population

The central theme of my research program is the development, implementation and evaluation of evidence-based care models for individual and population-level micro-elimination of HCV among provincial prison inmates. The core goal of this program is to ultimately increase treatment uptake among provincial prison inmates infected with chronic HCV by improving screening and linkage programs in Quebec provincial prisons. Support from the FRSQ will help me to address two overarching aims: (1) To determine the HCV screening test of choice among Quebec provincial prison inmates; and (2) To develop and evaluate the best approach to improving linkage to HCV care for recently released provincial prison inmates. The ultimate goal will be to use these findings to develop a micro-elimination care model that can be scaled up in other provincial prisons in Canada.

Based at the McGill University Health Centre, I am privileged to be part of a network of investigators conducting world-class innovative interdisciplinary research, ensuring that my current and future research studies benefit from local leading health outcomes researchers and methodologists.